News

3SBio Inc. and Verseau Therapeutics, Inc. announced a partnership agreement focused on the development and commercialization of novel monoclonal antibodies in the field of…
Read More...

Moberg Pharma AB has signed an exclusive license agreement with Bayer for commercialization of MOB-015 in Europe. Under the agreement, Moberg Pharma is eligible to receive up to EUR 50…
Read More...

GlaxoSmithKline plc and Merck KGaA, Darmstadt, Germany announced that they have entered into a global strategic alliance to jointly develop and commercialise M7824 (bintrafusp alfa).…
Read More...

Xencor announced it has entered into a research and license agreement with Genentech, a member of the Roche Group, to develop and commercialize novel IL-15 cytokine therapeutics,…
Read More...

Evotec AG and Galapagos NV announced a global collaboration focused on a novel target for fibrosis and other indications. The collaboration concerns a small molecule programme,…
Read More...

Fate Therapeutics announced that the U.S. Food and Drug Administration (FDA) has allowed its Investigational New Drug (IND) application for FT516, the Company’s off-the-shelf natural…
Read More...

Ligand Pharmaceuticals Incorporated announces it has entered into a worldwide OmniAb partnership with Genagon Therapeutics AB, an immuno-oncology focused biotech located in Sweden.…
Read More...

Cannabics Pharmaceuticals announced that it has entered into agreement with Wize Pharma, a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, and…
Read More...

BioMotiv, a drug development accelerator associated with The Harrington Project for Discovery & Development, and researchers from Rutgers, The State University of New Jersey,…
Read More...

Pathios Therapeutics and Sygnature Discovery sign strategic partnership to discover novel GPR65 modulators for the treatment of autoimmune disease and cancer. Pathios Therapeutics,…
Read More...

Taiho Pharmaceuticaland Cullinan Oncology announced on February 5 an agreement to develop TAS6417, a novel EGFR (epidermal growth factor receptor) tyrosine kinase inhibitor discovered…
Read More...

Novelion Therapeutics Inc. announced that its subsidiary, Aegerion Pharmaceuticals has entered into an exclusive licensing agreement with Recordati Rare Diseases Inc. for the…
Read More...

Taiho Pharmaceutical and Cullinan Oncology announced on February 5 an agreement to develop TAS6417, a novel EGFR (epidermal growth factor receptor) tyrosine kinase inhibitor discovered…
Read More...

Moderna, Inc., announced the dosing of the first subject in a Phase 1 clinical trial evaluating the safety and tolerability of escalating doses of mRNA-1944 via intravenous infusion in…
Read More...

AstraZeneca and its global biologics research and development arm, MedImmune, announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD)…
Read More...

The pivotal Phase 3 trial of isatuximab in patients with relapsed/refractory multiple myeloma met the primary endpoint of prolonging progression free survival in patients treated with…
Read More...

Trevi Therapeutics announced that it had entered into exclusive license agreements with Rutgers, The State University of New Jersey and MentiNova, Inc. for intellectual property and…
Read More...

IQVIA announced the launch of IQVIA Biotech and its new approach to delivering tailored clinical and commercial solutions for small biotech and biopharma companies. This solutions…
Read More...

Verseon’s phase 1 trial in healthy volunteers, which started dosing last week, could lead to a new treatment standard for millions of cardiac patients who would benefit from long-term…
Read More...

argenx and Halozyme Therapeutics announced a global collaboration and license agreement that enables use by argenx of Halozyme’s ENHANZE drug delivery technology to develop multiple…
Read More...